Sight Sciences announced FDA 510(k) clearance for its OMNI Ultra Surgical System, a minimally invasive glaucoma surgery (MIGS) device designed for single pass canaloplasty and trabeculotomy to reduce intraocular pressure in adults with primary open-angle glaucoma. The OMNI Ultra offers implant-free intervention addressing all three areas of aqueous outflow resistance through a single microincision, featuring TruSync Plus technology for enhanced control and precision. This clearance marks a significant advancement in glaucoma treatment, with the commercial launch planned for Q4 2026. The device supports both standalone and combined cataract surgeries, aiming to improve surgical outcomes and patient care.
Two directors of Equitable Holdings sold shares recently, with Bertram L. Scott selling 2,780 shares and Craig C. MacKay selling 2,000 shares. Meanwhile, institutional investors showed mixed activity: Engineers Gate Manager LP drastically cut its hol...
Shares of Greenland-linked mining companies surged following a new U.S.-Denmark-Greenland security agreement that boosted investor interest in Greenland's mineral resources. Greenland Mines Ltd. jumped over 229%, while Critical Metals Corp. rose near...
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
Priority Technology Holdings is being taken private in a $1.6 billion deal led by its Chairman and CEO, Thomas Priore. The acquisition price is $8.05 per share, matching the analyst price target set by Lake Street, which downgraded the stock to 'Hold...
General Mills is set to report its Q3 2026 earnings with an expected 16.3% decline in earnings per share to $0.72 and revenue forecast around $4.35 billion, down from last year. Despite these declines, the company reaffirmed its full-year adjusted EP...
